| scholarly article | Q13442814 |
| P2093 | author name string | Dan V Iosifescu | |
| James M Greenblatt | |||
| Daniel A Hoffman | |||
| Mark Schiller | |||
| P2860 | cites work | Borderline Personality Disorder | Q22250898 |
| Sertraline versus other antidepressive agents for depression | Q24241157 | ||
| Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
| Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. | Q33303429 | ||
| Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis | Q33444727 | ||
| The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study | Q33850634 | ||
| Appropriate use of psychotropic drugs in nursing homes | Q33874152 | ||
| Prescribing psychotropic medication for elderly patients: some physicians' perspectives | Q34031977 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design | Q34310720 | ||
| Schizophrenia, neuroleptic medication and mortality | Q34490208 | ||
| Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. | Q51942046 | ||
| Clinical impact of a 2-week psychotropic medication washout in unipolar depressed inpatients. | Q51947605 | ||
| Evaluation of a complex case: the value of a drug washout period. | Q51997857 | ||
| Bipolar disorder treatment: an evidence-based reality check. | Q60446979 | ||
| Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment | Q73008054 | ||
| Polypharmacy: when is it rational? | Q80112030 | ||
| Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care | Q34519650 | ||
| Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis. | Q34656488 | ||
| Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 | ||
| Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study | Q35030003 | ||
| Overcoming problems with polypharmacy and drug misuse in the elderly | Q36070309 | ||
| The road to recovery from depression--don't drive today with yesterday's map. | Q36910850 | ||
| Polypharmacy in elderly patients | Q37052260 | ||
| The STAR*D study: treating depression in the real world. | Q37072790 | ||
| When is antipsychotic polypharmacy supported by research evidence? Implications for QI. | Q37306729 | ||
| Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression | Q37548571 | ||
| Efficacy and effectiveness of antidepressants: current status of research | Q37771196 | ||
| Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. | Q38383710 | ||
| Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial | Q38486961 | ||
| For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians | Q39890729 | ||
| Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia | Q43149273 | ||
| Disruptive insights in psychiatry: transforming a clinical discipline | Q43154189 | ||
| Psychopharmacology: rational and irrational polypharmacy | Q43463430 | ||
| Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study | Q44022663 | ||
| The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development | Q44543027 | ||
| National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. | Q46655034 | ||
| Early risk factors for suicide in an epidemiological first episode psychosis cohort | Q46950538 | ||
| Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000. | Q47402814 | ||
| Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 | ||
| The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression | Q49144353 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 639-648 | |
| P577 | publication date | 2011-10-20 | |
| P1433 | published in | Neuropsychiatric Disease and Treatment | Q15716332 |
| P1476 | title | Polypharmacy or medication washout: an old tool revisited | |
| P478 | volume | 7 |
| Q48090742 | An Innovative, Interdisciplinary Model of Care for Inpatient Child Psychiatry: an Overview. |
| Q35217712 | Disparities in identification of comorbid diagnoses in children with ADHD. |
| Q37631543 | Factors affecting the development of adverse drug reactions (Review article) |
| Q38590584 | Interactions between behavior function and psychotropic medication |
| Q36091252 | Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic patients: a retrospective chart review |
| Q36722956 | Pharmacologic Therapy for Posttraumatic Stress Disorder: Review of Prescriptions and Potential Drug-Drug Interactions in a Military Cohort |
| Q37719619 | Potential drug interactions in patients with a history of cancer |
| Q47759193 | Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time |
| Q38786467 | The Ethics of Clinical Trials Research in Severe Mood Disorders |
| Q37214597 | The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy |
Search more.